NCT06943755 2026-02-27
STELLAR-311
Exelixis
Phase 2/3 Recruiting
Clinical Trials
7 trialsNCT07218575 2025-10-20
Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
Boston Children's Hospital
Phase 2/3 Not yet recruiting
NCT07165886 2025-09-10
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3 Recruiting
NCT05833815 2024-08-13
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Banaras Hindu University
Phase 2/3 Recruiting
NCT02860494 2021-05-03
EVEROST
Hospices Civils de Lyon
Phase 2/3 Withdrawn
NCT03285802 2020-02-05
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
Greater Baltimore Medical Center
Phase 2/3 Completed
NCT01730209 2015-05-05
RAPIT
Erasmus Medical Center
Phase 2/3 Unknown